Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

被引：0
|
作者：
Shweta Urva
Tonya Quinlan
John Landry
Xiaosu Ma
Jennifer A. Martin
Charles T. Benson
机构：
[1] Eli Lilly and Company,
[2] Lilly Corporate Center,undefined
来源：
Clinical Pharmacokinetics | 2022年 / 61卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1057 / 1067
页数：10
相关论文
共 50 条
  • [1] Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Ma, Xiaosu
    Martin, Jennifer A.
    Benson, Charles T.
    CLINICAL PHARMACOKINETICS, 2022, 61 (07) : 1057 - 1067
  • [2] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Urva, Shweta
    Quinlan, Tonya
    Landry, John
    Martin, Jennifer
    Loghin, Corina
    CLINICAL PHARMACOKINETICS, 2021, 60 (08) : 1049 - 1059
  • [3] Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
    Shweta Urva
    Tonya Quinlan
    John Landry
    Jennifer Martin
    Corina Loghin
    Clinical Pharmacokinetics, 2021, 60 : 1049 - 1059
  • [4] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [5] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    JCI INSIGHT, 2020, 5 (17)
  • [6] Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
    Schneck, Karen
    Urva, Shweta
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (03): : 494 - 503
  • [7] Tirzepatide, a dual GIP/GLP-1 receptor agonist, interrupts metabolic adaptation to dietary restriction
    Coskun, T.
    Roell, W. C.
    O'Farrell, L. S.
    Beebe, E. C.
    Regmi, A.
    Emmerson, P. J.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S58 - S59
  • [8] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [9] Role of Dual GIP and GLP-1 Receptor Agonist, Tirzepatide in the Management of Weight Loss; A Systematic Review
    Rangraze, Imran Rashid
    Khan, Shehla
    Wali, Adil Farooq
    Menezes, Godfred
    Goud, Manjunatha
    Jabran, Muhammad
    CURRENT DRUG SAFETY, 2024,
  • [10] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
12345